[Long-term remission in acute leukemia]. 1974

I F Korchmaru, and E I Sedykina, and P V Tereshchenko

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015122 Mercaptopurine An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. 6-Mercaptopurine,1,7-Dihydro-6H-purine-6-thione,6-Mercaptopurine Monohydrate,6-Thiohypoxanthine,6-Thiopurine,6H-Purine-6-thione, 1,7-dihydro-,BW 57-323H,Leupurin,Mecaptopurine Anhydrous,Mercaptopurina Wellcome,Puri-Nethol,Purimethol,Purinethol,6 Mercaptopurine,6 Mercaptopurine Monohydrate,6 Thiohypoxanthine,6 Thiopurine,BW 57 323H,BW 57323H

Related Publications

I F Korchmaru, and E I Sedykina, and P V Tereshchenko
January 1978, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
I F Korchmaru, and E I Sedykina, and P V Tereshchenko
January 1981, Neoplasma,
I F Korchmaru, and E I Sedykina, and P V Tereshchenko
October 1983, Klinische Wochenschrift,
I F Korchmaru, and E I Sedykina, and P V Tereshchenko
January 1979, Klinische Padiatrie,
I F Korchmaru, and E I Sedykina, and P V Tereshchenko
January 1976, Acta haematologica,
I F Korchmaru, and E I Sedykina, and P V Tereshchenko
March 2007, Leukemia research,
I F Korchmaru, and E I Sedykina, and P V Tereshchenko
March 2002, Leukemia & lymphoma,
I F Korchmaru, and E I Sedykina, and P V Tereshchenko
August 1987, [Rinsho ketsueki] The Japanese journal of clinical hematology,
I F Korchmaru, and E I Sedykina, and P V Tereshchenko
July 1976, Problemy gematologii i perelivaniia krovi,
I F Korchmaru, and E I Sedykina, and P V Tereshchenko
October 1970, Lancet (London, England),
Copied contents to your clipboard!